Nashville, TN, May 22, 2019 Vesalio announces it has obtained its second CE Approval spanning multiple new NeVa™ product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first to market features such as a distal filter. A controlled launch of the new technology will begin in June in Europe with expected full commercial release in Q4 of this year.
“We are excited to be granted our second CE Approval. The new technology looks very promising based on early feedback from several physician KOLs. The positive clinical results that were recently published from our first generation NeVa devices, has led to an increased market interest in NeVa. We are encouraged by our growth as we are nearing our first anniversary of commercialization. The expansion of the NeVa platform should provide an excellent opportunity for Vesalio to gain additional market share” commented Steve Rybka, CEO.
The paper entitled, “Mechanical thrombectomy with a novel stent retriever with multifunctional zones: Initial clinical experience with the NeVa™ thrombectomy device”, was recently published in the Journal of Neuroradiology. From the publication, NeVa demonstrated a high rate of first pass success and overall reperfusion scores with no device related complications.
About Vesalio, LLC.
Founded in 2013, Vesalio is a privately held medical device company focused on advancing technology needed to improve outcomes in stroke treatment. The Company’s proprietary NeVa™ platform was designed to achieve repeatable and superior clinical outcomes by providing physicians “first pass” success in effectively capturing and retaining a neurovascular clot inside the device.
For further information email
NeVa trademarks and patents are the property of Vesalio.